The potential of histone deacetylase inhibitors for the treatment of multiple myeloma

被引：11
|
作者：
Prince, H. Miles [1 ,2 ]
Bishton, Mark [1 ,2 ]
Harrison, Simon [1 ,2 ]
机构：
[1] Peter MacCallum Canc Ctr, Haematol Serv, Melbourne, Vic, Australia
[2] Univ Melbourne, Parkville, Vic 3052, Australia
来源：
LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 03期
关键词：
myeloma; neoplasia; histone; deacetylase;
D O I：
10.1080/10428190801950058
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Preclinical evidence supports the investigation of histone deacetylase inhibitors for the treatment of myeloma. Results from early studies demonstrate clinical activity and further studies investigating combination strategies should be explored.
引用
收藏
页码：385 / 387
页数：3
相关论文
共 50 条
  • [21] Epigenetic regulation of IFNs activity in multiple myeloma by histone deacetylase inhibitors.
    Cheriyath, Venugopalan
    Hussein, Mohamad A.
    Borden, Ernest C.
    CANCER RESEARCH, 2006, 66 (08)
  • [22] Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in multiple myeloma.
    Fandy, T
    Shankar, S
    Luetrakul, T
    Srivastava, R
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6164S - 6164S
  • [23] Potential of Histone Deacetylase 6 Inhibitors as a Treatment of Neurodegenerative Diseases
    Abdel-Magid, Ahmed F.
    ACS MEDICINAL CHEMISTRY LETTERS, 2025, 16 (02): : 210 - 212
  • [24] Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy
    Mohseni, Jafar
    Zabidi-Hussin, Z. A. M. H.
    Sasongko, Teguh Haryo
    GENETICS AND MOLECULAR BIOLOGY, 2013, 36 (03) : 299 - 307
  • [25] Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma
    Wahaib, Kristy
    Beggs, Ashton E.
    Campbell, Hope
    Kodali, Leela
    Ford, Patrick D.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (07) : 441 - 450
  • [26] The pharmaceutical potential of histone deacetylase inhibitors
    Elaut, Greetje
    Rogiers, Vera
    Vanhaecke, Tamara
    CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (25) : 2584 - 2620
  • [27] Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat
    Afifi, Salma
    Michael, Angela
    Azimi, Mahshid
    Rodriguez, Mabel
    Lendvai, Nikoletta
    Landgren, Ola
    PHARMACOTHERAPY, 2015, 35 (12): : 1173 - 1188
  • [28] Histone Deacetylase Inhibitors in the Treatment of Lymphoma
    Lemoine, Manuela
    Younes, Anas
    DISCOVERY MEDICINE, 2010, 10 (54) : 462 - 470
  • [29] Histone deacetylase inhibitors in cancer treatment
    Vigushin, DM
    Coombes, RC
    ANTI-CANCER DRUGS, 2002, 13 (01) : 1 - 13
  • [30] Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
    Chhabra, Saurabh
    PHARMACEUTICALS, 2017, 10 (02)
12345